Лекарственное лечение метастазов тройного негативного рака молочной железы

Jiayu Wang, Binghe Xu, Peng Yuan, Fei Ma, Qing Li, Pin Zhang, Ruigang Cai, Ying Fan, Yang Luo, Qiao Li, Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial. Cancer. ,vol. 121, pp. 3412- 3421 ,(2015) , 10.1002/CNCR.29492

Joyce F. Liu, Sara M. Tolaney, Michael Birrer, Gini F. Fleming, Mary K. Buss, Suzanne E. Dahlberg, Hang Lee, Christin Whalen, Karin Tyburski, Eric Winer, Percy Ivy, Ursula A. Matulonis, A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. European Journal of Cancer. ,vol. 49, pp. 2972- 2978 ,(2013) , 10.1016/J.EJCA.2013.05.020

Lisa Carey, Eric Winer, Giuseppe Viale, David Cameron, Luca Gianni, Triple-negative breast cancer: disease entity or title of convenience? Nature Reviews Clinical Oncology. ,vol. 7, pp. 683- 692 ,(2010) , 10.1038/NRCLINONC.2010.154

Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew N. J. Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M. B. Martin, Stephen P. Jackson, Graeme C. M. Smith, Alan Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature. ,vol. 434, pp. 917- 921 ,(2005) , 10.1038/NATURE03445

Dmitry Malin, Feng Chen, Carol Schiller, Jennifer Koblinski, Vincent L. Cryns, Enhanced Metastasis Suppression by Targeting TRAIL Receptor 2 in a Murine Model of Triple-Negative Breast Cancer Clinical Cancer Research. ,vol. 17, pp. 5005- 5015 ,(2011) , 10.1158/1078-0432.CCR-11-0099

Richard S. Finn, Judy Dering, Charles Ginther, Cindy A. Wilson, Padraic Glaspy, Nishan Tchekmedyian, Dennis J. Slamon, Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment. ,vol. 105, pp. 319- 326 ,(2007) , 10.1007/S10549-006-9463-X

T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siolek, S. A. Narod, J. Lubinski, , Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers Breast Cancer Research and Treatment. ,vol. 108, pp. 289- 296 ,(2008) , 10.1007/S10549-007-9600-1

G.S. Bhattacharyya, S. Basu, V. Agarwal, H. Malhotra, P.M. Pareekh, K.G. Babu, D. Aggarwala, 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative Ejc Supplements. ,vol. 7, pp. 18- 19 ,(2009) , 10.1016/S1359-6349(09)72076-2

C Colpaert, P Vermeulen, P van Beest, G Goovaerts, J Weyler, P Van Dam, L Dirix, E Van Marck, Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology. ,vol. 39, pp. 416- 425 ,(2001) , 10.1046/J.1365-2559.2001.01238.X

J Baselga, S Stemmer, A Pego, A Chan, J-C Goeminne, M-P Graas, J Kennedy, EM Ciruelos Gil, A Zubel, J Groos, U Kia, A. Schneeweiss, Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial Cancer Research. ,vol. 70, ,(2010) , 10.1158/0008-5472.SABCS10-PD01-01